Antigen-Specific Immunomodulation via Segmented HLA Presentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective solutions for modulating immune activity specifically towards preselected antigens, which is crucial for managing autoimmune diseases and immune-related disorders.
Innovation Solution
A pharmaceutical composition comprising a mixture of partially purified HLA proteins, heat-treated blood components, and alpha-synuclein proteins, combined with preselected antigens, is developed to modulate immune responses. This composition can be administered to enhance or suppress immune reactions as needed, depending on the antigen-specific requirements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional immune modulation methods are used, then general immune response can be affected, but antigen-specific immune modulation cannot be achieved
Solution Approach 1:
The patent segments the immune modulation process by using antigen-presenting cells that are specifically loaded with predetermined antigens. This segmentation allows the immune system to be modulated in a targeted manner toward specific antigens while leaving other immune responses unaffected, thereby achieving antigen-specific immune modulation with high precision and reliability
Solution Approach 2:
The patent employs antigen-presenting cells as intermediaries between the predetermined antigens and the immune system. These cells process and present the antigens in a controlled manner, enabling specific immune responses to be triggered only against the selected antigens, thus resolving the contradiction between antigen-specificity and effectiveness
2Object-affected harmful factors
If broad-spectrum immunosuppression is applied, then autoimmune diseases may be treated, but non-specific immune function is compromised
Solution Approach 1:
The patent applies local quality by directing immunosuppressive effects only to immune responses against specific predetermined antigens. By using antigen-specific antigen-presenting cells, the treatment creates localized immunomodulation at the antigen-specific level while preserving the adaptability and versatility of the overall immune system against other pathogens and threats
3Reliability
If complex immunomodulation protocols are used, then immune responses can be modulated, but treatment complexity and patient burden increase
Solution Approach 1:
The patent employs preliminary action by pre-loading antigen-presenting cells with predetermined antigens before administration to the patient. This preparatory step simplifies the treatment protocol, as the antigen-specific immune modulation is achieved through a single administration rather than complex multi-step protocols, thereby maintaining high efficacy while reducing treatment complexity and patient burden
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively induces antigen-specific immune modulation, as demonstrated by enhanced immune responses or immunosuppressive effects, providing a potential therapeutic approach for autoimmune diseases and immune disorders.
Implementation Method 1
At least the first component or only the first component may be heat-treated, for example, heat-treated at or above 100° C. for at least 1 or 2 or 3 or 4 or 5 minutes. The at least partially purified HLA protein or other proteins may be at least substantially denatured. The proteins may at least partially, such as at least substantially, be fragmented into peptides.
Data Source
AI summary
Provided are immunomodulatory pharmaceutical compositions that include alpha-synuclein, and at least one preselected antigen, such as at least one preselected peptide antigen or immunogen. Also provided are methods for modulating immune activity toward at least one preselected antigen in an at least substantially antigen-specific manner that includes administering such a composition to a human patient or a non-human mammalian subject.